BMJ  2004;328:358-359 (14 February), doi:10.1136/bmj.328.7436.358

Editorial

Thalassaemia major: the murky story of deferiprone

Conducting life saving research properly and quickly is a moral imperative

The first 150 words of the full text of this article appear below.

Every year over 200 000 babies are born with thalassaemia major. They have a life expectancy of less than 30 years and are dependent on blood transfusions. Repeated transfusions result in cirrhosis of the liver, cardiomyopathy, endocrinopathies, and death due to haemosiderosis. Desferoxamine, an iron chelator, has been used for more than 30 years to treat haemosiderosis. It is given by daily, subcutaneous, slow injection, with inconvenience and local reactions resulting in suboptimal compliance in about half the patients.¹ Despite desferoxamine, cardiac disease is still responsible for 70% of all deaths in these patients. Developing an orally administered chelating agent has therefore been a major objective in the care of patients with thalassaemia. Unfortunately the development of such a drug (deferiprone) has resulted in one of the most acrimonious and destructive of conflicts between a clinical researcher (Nancy Olivieri) and a drug company (Apotex).^{2 w1-w4} This dispute raises several ethical issues, . . . [Full text of this article]

Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford OX1 1PT (julian.savulescu@philosophy.oxford.ac.uk)

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Article

Abusing patients by denying them choice

Richard Smith
BMJ 2004 328: 0. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Saunders, R, Savulescu, J (2008). Research ethics and lessons from Hwanggate: what can we learn from the Korean cloning fraud?. J. Med. Ethics 34: 214-221 [Abstract] [Full text]  

Rapid Responses:

Read all Rapid Responses

Seeking the truth on deferiprone: an orphan drug for a market worth hundreds of millions.

George J Kontoghiorghes
bmj.com, 18 Feb 2004 [Full text]

Seeking the truth on deferiprone: an orphan drug for a market worth hundreds of millions.

George J Kontoghiorghes
bmj.com, 18 Feb 2004 [Full text]

Abuse of patients' rights in the name of research integrity

Panos A Ioannou
bmj.com, 5 Apr 2004 [Full text]

Independence of local ethics review

Mark H Wilson
bmj.com, 9 Mar 2004 [Full text]

The disappearing patient

George Constantinou
bmj.com, 13 Mar 2004 [Full text]

Response to Savulescu Editorial. RE: Deferiprone

A. Victor Hoffbrand
bmj.com, 19 Mar 2004 [Full text]

THE TRUE ETHICS OF THE DEFERIPRONE DEBATE

Michael Spino, et al.
bmj.com, 5 Apr 2004 [Full text]

To the Editor

Nancy F Olivieri
bmj.com, 1 Apr 2004 [Full text]

Online poll

Find out more here>> and here>>